Viral interaction: A possible contributing factor in head and neck cancer progression

Acta Oto-Laryngologica

Volumn 128, Issue 12, 2008, Pages 1361-1369

  Underbrink, Michael P ^a   Hoskins, Stephen L ^a   Pou, Anna M ^a,b   Albrecht, Thomas ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

E6; E7; Head and neck cancer; HPV; Human herpesvirus 8; Human papillomavirus; ORF 50

Indexed keywords

PROTEIN E6; PROTEIN E7; PROTEIN RTA; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ARTICLE; BINDING SITE; CANCER GROWTH; CELL CYCLE; CONFOCAL MICROSCOPY; DISEASE ASSOCIATION; GENE EXPRESSION; GENETIC TRANSCRIPTION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; MORBIDITY; MORTALITY; OPEN READING FRAME; PRIORITY JOURNAL; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; UPREGULATION; VIRUS ATTACHMENT;

BINDING SITES; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, VIRAL; GENOME, VIRAL; HEAD AND NECK NEOPLASMS; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMEDIATE-EARLY PROTEINS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; PROTEIN BINDING; REPRESSOR PROTEINS; RNA, VIRAL; TRANS-ACTIVATORS; TRANSCRIPTION, GENETIC;

EID: 57349110655     PISSN: 00016489     EISSN: 16512553     Source Type: Journal    
DOI: 10.1080/00016480801965001     Document Type: Article

References (20)

1. Barbosa MS. The oncogenic role of human papillomavirus proteins. Crit Rev Oncog 1996;7:1-18.
2. Dekmezian RH, Batsakis JG, Goepfert H. In situ hybridization of papillomavirus DNA in head and neck squamous cell carcinomas. Arch Otolaryngol Head Neck Surg 1987;113:819-21.
3. Miller CS, White DK. Human papillomavirus expression in oral mucosa, premalignant conditions, and squamous cell carcinoma: a retrospective review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996;82:57-68.
4. Francis DA, Schmid SI, Howley PM. Repression of the integrated papillomavirus E6/E7 promoter is required for growth suppression of cervical cancer cells. J Virol 2000;74:2679-86.
5. Munger K, Phelps WC, Bubb V, Howley PM, Schlegel R. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol 1989;63:4417-21.
6. Smith EM, Summersgill KF, Allen J, Hoffman HT, McCulloch T, Turek LP, et al. Human papillomavirus and risk of laryngeal cancer. Ann Otol Rhinol Laryngol 2000;109:1069-76.
7. zur Hausen H. Viruses in human cancers. Science 1991;254:1167-73.
8. Knowles DM, Cesarman E. The Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) in Kaposi's sarcoma, malignant lymphoma, and other diseases. Ann Oncol 1997;/8(Suppl 2):/123-9.
9. Pauk J, Huang ML, Brodie SJ, Wald A, Koelle DM, Schacker T, et al. Mucosal shedding of human herpesvirus 8 in men. N Engl J Med 2000;343:1369-77.
10. West JT, Wood C. The role of Kaposi's sarcoma-associated herpesvirus/human herpesvirus-8 regulator of transcription activation (RTA) in control of gene expression. Oncogene 2003;22:5150-63.
11. Lagunoff M, Ganem D. The structure and coding organization of the genomic termini of Kaposi's sarcoma-associated herpesvirus. Virology 1997;236:147-54.
12. Gradoville L, Gerlach J, Grogan E, Shedd D, Nikiforow S, Metroka C, et al. Kaposi's sarcoma-associated herpesvirus open reading frame 50/Rta protein activates the entire viral lytic cycle in the HH-B2 primary effusion lymphoma cell line. J Virol 2000;74:6207-12.
13. Lukac DM, Garibyan L, Kirshner JR, Palmeri D, Ganem D. DNA binding by Kaposi's sarcoma-associated herpesvirus lytic switch protein is necessary for transcriptional activation of two viral delayed early promoters. J Virol 2001;75:6786-99.
14. Wang S, Liu S, Wu M, Geng Y, Wood C. Kaposi's sarcoma-associated herpesvirus/human herpesvirus-8 ORF50 gene product contains a potent C-terminal activation domain which activates gene expression via a specific target sequence. Arch Virol 2001;146:1415-26.
15. Cox M, Maitland N, Scully C. Human herpes simplex-1 and papillomavirus type 16 homologous DNA sequences in normal, potentially malignant and malignant oral mucosa. Eur J Cancer 1993;29B:215-9.
16. Iwasaka T, Yokoyama M, Hayashi Y, Sugimori H. Combined herpes simplex virus type 2 and human papillomavirus type 16 or 18 deoxyribonucleic acid leads to oncogenic transformation. Am J Obstet Gynecol 1988;159:1251-5.
17. Hara Y, Kimoto T, Okuno Y, Minekawa Y. Effect of herpes simplex virus on the DNA of human papillomavirus 18. J Med Virol 1997;53:4-12.
18. Ke LD, Adler-Storthz K, Mitchell MF, Clayman GL, Chen Z. Expression of human papillomavirus E7 mRNA in human oral and cervical neoplasia and cell lines. Oral Oncol 1999;35:415-20.
19. Caselli E, Menegazzi P, Bracci A, Galvan M, Cassai E, Di Luca D. Human herpesvirus-8 (Kaposi's sarcoma-associated herpesvirus) ORF50 interacts synergistically with the tat gene product in transactivating the human immunodeficiency virus type 1 LTR. J Gen Virol 2001;82(Pt 8):1965-70.
20. Deng H, Chu JT, Rettig MB, Martinez-Maza O, Sun R. Rta of the human herpesvirus 8/Kaposi sarcoma-associated herpesvirus up-regulates human interleukin-6 gene expression. Blood 2002;100:1919-21.